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Supplementary methods: Data management
Clinical data were entered by study staff on electronic source tablet PCs with preprogrammed edit checks (Clinical Ink, Winston Salem, NC), with weekly electronic transfers to the core database. TB lab results were processed by double data entry or electronic transfer, depending on lab, and underwent 100% source data verification. ECG data and South African safety lab data were uploaded electronically; Tanzanian safety lab data were entered manually.
Definition of primary endpoint
Two consecutive negative sputum cultures without intervening positive, contaminated or missing cultures were required for the primary endpoint. Intermittent missing or contaminated culture results between follow up visits were effectively imputed as positive (i.e. assuming worst case scenario). All primary and secondary analyses were done on the modified intention-to-treat population (all randomized patients without evidence of rifampicin resistance on phenotypic test who took at least one dose of study treatment with an available outcome and who had at least one positive culture result at screening, week 1 or week 2 either on liquid or solid media).
Sensitivity analyses and analysis of secondary endpoints
The following secondary efficacy endpoints were pre-specified in the statistical analysis plan: In post hoc analyses, time to stable culture conversion to negative in liquid culture and on solid culture up to 8 weeks was done for comparability with previous TB phase II trials and also the same endpoints ignoring missing and contaminated cultures as post hoc sensitivity analyses.
Two further post hoc analyses: a repeat of the primary analysis of the primary endpoint excluding patients with resistance to drug to which they were allocated, and an analysis of time to stable culture conversion to negative on solid culture up to 12 weeks excluding patients without evidence of culture positivity on solid media. Table S1 : Inclusion and Exclusion criteria
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Inclusion Criteria
Each patient must meet all of the following inclusion criteria prior to enrolment into the study:
1. The patient has given free, signed written or witnessed oral informed consent for study participation prior to all trial-related procedures, including HIV testing if HIV serostatus is not known or the last documented negative is more than four weeks ago.
2. The patient has a diagnosis of pulmonary tuberculosis from a health clinic established by sputum smear and/or GeneXpert MTB/RIF® and/or chest X-ray.
3. An adequate sputum bacterial load is confirmed by a Ziehl-Neelsen stained smear in the study laboratory, done from concentrated sputum found at least 1+ on the IUATLD/WHO scale.
4. The patient has rapid tests performed in the study laboratory from the screening sputum sample(s), with the following results: -GeneXpert MTB/RIF®positive for MTB complex, and indicating susceptibility to Rifampicin, -Line probe assay (e.g. HAIN MTBDRplus) result not indicating resistance to rifampicin or isoniazid. -In case of an inconclusive result, this test is to be repeated at least once. Should the repeat test result again be inconclusive, the patient may continue with enrolment without this result.
5. The patient is aged at least 18 years at the day of informed consent.
6. The patient has a body weight in light clothing and without shoes of at least 35 kg, but not more than 90 kg.
7. Female patients of childbearing potential must have a negative serum pregnancy test, and consent to practise an effective method of birth control until week 26. Effective birth control for female patients has to include two methods, including methods that the patient's sexual partner(s) use. At least one must be a barrier method. Female patients are considered not to be of childbearing potential if they are post-menopausal with no menses for the last 12 months, or surgically sterile (this condition is fulfilled by bilateral oophorectomy, hysterectomy, and by tubal ligation which is done at least 12 months prior to enrolment).
8. Male patients must consent to use an effective contraceptive method, if their sexual partner(s) is/are of childbearing potential, and if they are not surgically sterile (see 6.).
Contraception by male participants must be practised until at least week 24 to cover the period of spermatogenesis. Contraceptive methods used by male participants may include hormonal methods used by the partner(s).
9. The patient has a firm home address that is readily accessible for visiting and willingness to inform the study team of any change of address during trial participation, or will be compliant to study schedule, in the discretion of the investigator.
Exclusion Criteria
Patients for whom one of the following criteria is met will be excluded from trial:
1. Circumstances that raise doubt about free, uncoerced consent to study participation (e.g. in a prisoner or mentally handicapped person)
2. Poor General Condition where delay in treatment cannot be tolerated or death within three months is likely.
3. The patient is pregnant or breast-feeding.
4. The patient has an HIV infection, and is receiving antiretroviral treatment (ART), and/or has less than 200 cd4 cells/µl, and/or is likely to require ART during the twelve weeks of experimental study treatment. Inclusion of HIV positive patients is only possible with specific approval from the site's local ethics committee.
5. The patient has a known intolerance to any of the study drugs, or concomitant disorders or conditions for which SQ109, rifampicin, moxifloxacin, or standard TB treatment are contraindicated.
6. The patient has an history or evidence of clinically relevant metabolic, gastrointestinal, neurological, psychiatric or endocrine diseases, malignancy, or any other condition that will influence treatment response, study adherence or survival in the judgement of the investigator, especially:
 clinically significant evidence of severe TB (e.g. miliary TB, TB meningitis. Limited lymph node involvement will not lead to exclusion)  serious lung conditions other than TB or severe respiratory impairment in the discretion of the investigator;  neuropathy, epilepsy or significant psychiatric disorder;  uncontrolled and/or insulin-dependent diabetes cardiovascular disease such as myocardial infarction, heart failure, coronary heart disease, uncontrolled hypertension (systolic blood pressure ≥160 mmHg and/or diastolic blood pressure of ≥100 mmHg on two occasions), arrhythmia, or tachyarrhythmia.  long QT syndrome (see criterion 9.), or family history of long QT syndrome or sudden death of unknown or cardiac-related cause Plasmodium spp. parasitemia as indicated by thick blood smear or a positive rapid test present at screening Alcohol or other drug abuse that is sufficient to significantly compromise the safety or cooperation of the patient, includes substances prohibited by the protocol, or has led to significant organ damage at the discretion of the investigator.
7. History of previous TB within the last five years. 
The patient has had treatment with any other investigational drug within 1 month prior to enrolment, or enrolment into other clinical (intervention) trials is planned during week 1-26
11. Previous anti-TB treatment: the patient has had previous treatment with drugs active against M. tuberculosis within the last 3 months, including but not limited to INH, EMB, RIF, PZA, amikacin, cycloserine, rifabutin, streptomycin, kanamycin, para-aminosalicylic acid, rifapentine, thioacetazone, capreomycin, fluoroquinolones, thioamides.
12. QT prolonging medications: Administration within 30 days prior to study start, anticipated administration during the study period, or during the 12 weeks of experimental treatment, of any QTprolonging agents such as, but not limited to, azithromycin, bepridil chloroquine, chlorpromazine, cisapride, cisapride, clarithromycin, disopyramide dofetilide, domperidone, droperidol, erythromycin, halofantrine, haloperidol, ibutilide, levomethadyl, lumefantrine, mefloquine, mesoridazine, methadone, moxifloxacin, pentamidine, pimozide, procainamide, quinidine, quinine, roxithromycin, sotalol, sparfloxacin, terfenadine, thioridazine.
Exceptions may be made for participants who have received 3 days or less of one of these drugs or substances, if there has been a wash-out period equivalent to at least 5 half-lives of that drug or substance.
Patients who have ever received amiodarone will be excluded from study participation.
13. CYP 450 inducers/inhibitors: administration within 30 days prior to dosing, or planned administration until the end of week 12, of any drug(s) or substance(s) known to be strong inhibitors or inducers of cytochrome P450 enzymes, or specific inhibitors/inducers of SQ109-metabolizing enzymes as listed in section 9.4.1 (p.56) and Appendix 3.
Exceptions may be made for subjects that have received 3 days or less of one of these drugs or substances, if a wash-out period equivalent to at least 5 half-lives of that drug or substance prior to study treatment is granted. * The Kaplan-Meier estimator has been used to estimate the proportions of patients converting to negative sputum culture by specific times as this more accurately accounts for censoring and loss to follow-up and corresponds to the data in Figure 2 in the main paper. Figure S1 : dose per body weight of all drugs dosed according to weight.
Plotted points correspond to study patients. Figure S2 . Pharmacokinetics of rifampicin A. Pharmacokinetic curves of rifampicin (means and 1 standard deviation)
